U.S. FDA accepts licensing application for pimavanserin to treat dementia patients with hallucinations and delusions

Pimavanserin, a selective 5-HT2A inverse agonist, is already approved in US for treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. FDA is set to review this licence extension application in April 2021.


Reuters Health